Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery

Inclusion Criteria: * Hepatocellular carcinoma confirmed with pathology or identified with radiological images with typical features * Age ≥ 18 years and ≤ 75 years * At least one tumor nodule with one uni-dimension of ≥ 2 cm * Child-Pugh Class A or B * HBV-DNA\>10\^4 * Total bilirubin ≤ 1.5 x upper limit of normal * ALT and AST ≤ 2.0 x the upper limit of normal * PT-INR\<2.3,PTT \< 1.5 x upper limit of normal * Serum creatinine ≤ 1.5x upper limit of normal * Peripheral white blood cell count of or more than 3×10(9)/L * Peripheral platelet of or more than 50×10(9)/L * Expected survival time not less than 3 months * ECOG score 0-2 Exclusion Criteria: * Tumor thrombi in main branch of portal vein * Tumor involvement more than 70% of whole liver * With extrahepatic metastasis * Prior systemic chemotherapy or chemoembolization * Congestive heart failure \> NYHA class 2 * History of HIV infection * Active clinically serious infections (\> 2 NCI-CTC Version 3.0) * Recurrence of HCC after liver transplantation * Pregnant or breast-feeding * Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in this study * Known or suspected allergy to any agent given in association with this trial * Patients unable to swallow oral medication * Inclined to thrombosis * Inclined to hemorrhage or active hemorrhage with 1 month